R Devaki Priyanka, Arunachalam Sundaram, Amitkumar Kalaivani, John Jaison Jacob, Sudalaimuthu Muthu
Department of Pathology, SRM Medical College Hospital and Research Centre, Chennai, IND.
Cureus. 2023 Jan 24;15(1):e34155. doi: 10.7759/cureus.34155. eCollection 2023 Jan.
Background Cervical carcinoma is one of the most prevalent cancers affecting women worldwide. Studies on Ki-67 expression in cervical lesions had focused mainly on the intraepithelial lesions of the cervix and not much on invasive carcinomas. The few studies published so far on Ki-67 expression in invasive cervical carcinomas have shown inconsistent results on the association of Ki-67 with various clinicopathological prognostic factors. Aims and objectives To assess Ki-67 expression in cervical carcinomas and to compare it with various clinicopathological prognostic factors. Materials and methods Fifty cases of invasive squamous cell carcinoma (SCC) were included in the study. Histological patterns and grades were identified and noted in these cases after microscopic examination of the histological sections. Immunohistochemical (IHC) staining with anti-Ki-67 was done and scored from 1+ to 3+. This score was compared with clinicopathological prognostic factors like clinical stage, histological pattern, and grade. Result Among the 50 cases of SCC, 41 showed keratinizing pattern (82%) and nine showed non-keratinizing pattern (18%). Four were in stage I, 25 were in stage II, and 21 were in stage III. Overall, 34 (68%) cases had Ki-67 score 3+, 11 (22%) had Ki-67 score 2+, and five (10%) had Ki-67 score 1+. Ki-67 score of 3+ was the most common score in keratinizing SCC (75.6%), poorly differentiated carcinomas (76.2%), and stage III cases (81%). Conclusion We observed statistically significant correlation of Ki-67 expression with higher clinical stage, keratinizing tumours, and poorly differentiated tumours (p<0.05) indirectly implying the poor prognostic significance of this marker.
宫颈癌是全球影响女性的最常见癌症之一。关于Ki-67在宫颈病变中的表达研究主要集中在宫颈上皮内病变,而对浸润性癌的研究较少。迄今为止发表的关于浸润性宫颈癌中Ki-67表达的少数研究,在Ki-67与各种临床病理预后因素的关联方面显示出不一致的结果。
评估Ki-67在宫颈癌中的表达,并将其与各种临床病理预后因素进行比较。
本研究纳入50例浸润性鳞状细胞癌(SCC)病例。在对组织切片进行显微镜检查后,确定并记录这些病例的组织学模式和分级。采用抗Ki-67进行免疫组织化学(IHC)染色,并评分为1+至3+。将该评分与临床分期、组织学模式和分级等临床病理预后因素进行比较。
在50例SCC病例中,41例表现为角化型(82%),9例表现为非角化型(18%)。4例处于I期,25例处于II期,21例处于III期。总体而言,34例(68%)病例的Ki-67评分为3+,11例(22%)为2+,5例(10%)为1+。Ki-67评分为3+是角化型SCC(75.6%)、低分化癌(76.2%)和III期病例(81%)中最常见的评分。
我们观察到Ki-67表达与较高临床分期、角化型肿瘤和低分化肿瘤之间存在统计学显著相关性(p<0.05),间接表明该标志物预后意义较差。